On March 11, 2024 Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, reported that it has been selected to give two oral presentations at the Keystone Symposium on Cancer Immunotherapy: Beyond Immune Checkpoint Blockade and Overcoming Resistance, taking place March 17-21, 2024, in Whistler, Canada (Press release, Compugen, MAR 11, 2024, View Source [SID1234641032]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We are delighted to be selected to give two oral presentations at the upcoming Keystone Symposium on Cancer Immunotherapy this year," said Anat Cohen-Dayag, Ph.D., President, and CEO of Compugen. "We believe our selection to present at a Keystone Symposium reflects the significant discovery, research and development taking place at Compugen as we are working to advance our vision to transform patient lives by developing first-in class therapeutics based on our computational target discovery platform."
Presentation & poster details
Oral presentation date:
Tuesday, March 19, 2024
Session title:
Novel insights into T Cell Biology
Lead author and presenter:
Dr. Assaf Menachem, Ph.D., Compugen
Presentation & poster title:
Unleashing Natural IL-18 Activity Using an Anti-IL-18BP Blocker Antibody Induces Potent Immune
Stimulation and Anti-tumor Effects
Poster date:
Tuesday, March 19, 2024
Poster number:
Poster #2042
Oral presentation date:
Tuesday, March 19, 2024
Oral session title:
Progress in Drugging the TIGIT and VISTA Pathways
Lead author and presenter:
Dr. Zoya Alteber, Ph.D., Compugen
Presentation & poster title:
PVRIG is Uniquely Expressed in Tumor Dendritic Cell-rich Niches on Stem-like Memory T Cells and
its Blockade May Induce Immune Infiltration and Activation in Non-inflamed Tumors
Poster date:
Monday, March 18, 2024
Poster number:
Poster #1001
The abstracts are available on the publication section of Compugen’s website www.cgen.com.
The presentations and posters will be made available on www.cgen.com, on the day of presentation.